Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Harvard Business School
Boehringer Ingelheim
Medtronic
Mallinckrodt

Last Updated: December 6, 2022

CLINICAL TRIALS PROFILE FOR DICLOFENAC


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


505(b)(2) Clinical Trials for Diclofenac

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT02068859 ↗ Treatment of Knee Pain With Topical Diclofenac Cream 8% or Diclofenac Gel 1% Unknown status FPR Specialty Pharmacy Phase 3 2014-01-01 Non-steroidal anti-inflammatory medication (NSAID) therapy is a mainstay treatment for joint pain and painful musculoskeletal disorders. Though this form of systemic therapy is highly effective, it causes substantial side effects including gastritis and gastric ulcer disease, renal impairment, hypertension, and thrombotic events. These types of oral medications are utilized by millions of Americans on a fairly regular basis in both over-the-counter preparations and prescription compounds. In recent years, topical preparations of NSAIDs have been used for localized pain as an alternate to oral administration with reported good analgesic efficacy. For example, they are often used for knee pain. There is little systemic absorption of NSAIDs with topical administration, and consequently less likelihood of systemic side effects. Though much less studied than oral NSAIDs, topical NSAID preparations are currently prescribed for a variety of arthritic and musculoskeletal types of pain. The best-studied commercially available products are diclofenac 1% compounds. Higher concentrations presumably provide higher tissue concentration leading to better and longer pain relief, along with a more prominent anti-inflammatory effect. The investigators will therefore compare the efficacy of available topical diclofenac 1% gel to that of diclofenac 8% cream. Specifically, the investigators propose to test the hypothesis that efficacy of topical diclofenac 8% exceeds that of diclofenac 1%, without any increase in systemic toxicity. One hundred six patients presenting to the Cleveland Clinic Pain Management Department for the treatment of knee pain will be randomly assigned to topical diclofenac cream 8% or diclofenac gel 1%, with the designated medication applied the symptomatic area of the knee over 6 weeks. Investigators will be blinded to treatment, and will evaluate pain relief and functional/disability status.
New Formulation NCT03766984 ↗ Pharmacokinetic Non-interaction Study With a Fixed-dose Combination Tablet With Tramadol and Diclofenac Completed Grünenthal Colombiana S.A. Phase 1 2015-06-07 The objective of the study was to evaluate whether or not there is a substantial pharmacokinetic interaction between diclofenac and tramadol in a new formulation of a fixed-dose combination of diclofenac 25 milligrams (mg) and tramadol 25 mg for oral administration. The study was conducted in healthy participants of both genders.
New Formulation NCT03766984 ↗ Pharmacokinetic Non-interaction Study With a Fixed-dose Combination Tablet With Tramadol and Diclofenac Completed Grünenthal S.A. Phase 1 2015-06-07 The objective of the study was to evaluate whether or not there is a substantial pharmacokinetic interaction between diclofenac and tramadol in a new formulation of a fixed-dose combination of diclofenac 25 milligrams (mg) and tramadol 25 mg for oral administration. The study was conducted in healthy participants of both genders.
New Formulation NCT03766984 ↗ Pharmacokinetic Non-interaction Study With a Fixed-dose Combination Tablet With Tramadol and Diclofenac Completed Grünenthal GmbH Phase 1 2015-06-07 The objective of the study was to evaluate whether or not there is a substantial pharmacokinetic interaction between diclofenac and tramadol in a new formulation of a fixed-dose combination of diclofenac 25 milligrams (mg) and tramadol 25 mg for oral administration. The study was conducted in healthy participants of both genders.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Diclofenac

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00090181 ↗ Study of MK0663 in Patients With Chronic Low Back Pain (0663-806)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 4 2004-06-01 The purpose of this study is to evaluate the efficacy of MK0663 for the treatment of chronic low back pain and to investigate the overall safety and tolerability over four weeks of treatment.
NCT00092378 ↗ A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2003-09-01 This purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following bunionectomy surgery.
NCT00092703 ↗ Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2002-06-27 The purpose of this study is to compare the gastrointestinal tolerability of an investigational drug to an approved drug in the treatment of osteoarthritis during one year treatment period.
NCT00092742 ↗ Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072) Completed Merck Sharp & Dohme Corp. Phase 3 2003-02-01 The purpose of this study is to evaluate the long-term safety of an investigational drug versus an approved drug for the relief of pain in patients with rheumatoid arthritis.
NCT00108992 ↗ Efficacy and Safety of Topical Diclofenac Combined With Oral Diclofenac in the Treatment of Knee Osteoarthritis Completed Nuvo Research Inc. Phase 3 2004-02-01 Oral non-steroidal anti-inflammatory drugs (NSAIDs) are a recommended treatment for the symptoms of osteoarthritis of the knee. However, NSAIDs may cause a range of negative side effects, including stomach pain, heartburn, bleeding stomach ulcer, and liver or kidney abnormality. A topical NSAID may relieve pain and other symptoms of osteoarthritis of the knee, while minimizing the side effects common to oral NSAIDs. The purpose of this study is to determine the safety and effectiveness of a topical NSAID when used alone or when combined with an oral NSAID in the treatment of osteoarthritis of the knee.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Diclofenac

Condition Name

Condition Name for Diclofenac
Intervention Trials
Pain 50
Osteoarthritis 23
Postoperative Pain 16
Pain, Postoperative 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Diclofenac
Intervention Trials
Osteoarthritis 55
Pain, Postoperative 49
Osteoarthritis, Knee 34
Acute Pain 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Diclofenac

Trials by Country

Trials by Country for Diclofenac
Location Trials
United States 440
United Kingdom 68
India 41
Germany 37
Egypt 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Diclofenac
Location Trials
Texas 32
Florida 29
California 26
Pennsylvania 21
Alabama 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Diclofenac

Clinical Trial Phase

Clinical Trial Phase for Diclofenac
Clinical Trial Phase Trials
Phase 4 121
Phase 3 94
Phase 2/Phase 3 12
[disabled in preview] 49
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Diclofenac
Clinical Trial Phase Trials
Completed 266
Unknown status 45
Recruiting 36
[disabled in preview] 40
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Diclofenac

Sponsor Name

Sponsor Name for Diclofenac
Sponsor Trials
Novartis 18
Cairo University 18
Pfizer 14
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Diclofenac
Sponsor Trials
Other 326
Industry 189
U.S. Fed 7
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Harvard Business School
Mallinckrodt
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.